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Abstract
Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims observa-
tional cohort study was to compare the risk of bleeding among non-valvular atrial fibrillation
(NVAF) patients prescribed apixaban, dabigatran, or rivaroxaban. NVAF patients aged�18
years with a 1-year baseline period were included if they were new initiators of NOACs or
switched from warfarin to a NOAC. Cox proportional hazards modelling was used to esti-
mate the adjusted hazard ratios of any bleeding, clinically relevant non-major (CRNM)
bleeding, and major inpatient bleeding within 6 months of treatment initiation for rivaroxaban
and dabigatran compared to apixaban. Among 60,227 eligible patients, 8,785 were pre-
scribed apixaban, 20,963 dabigatran, and 30,529 rivaroxaban. Compared to dabigatran or
rivaroxaban patients, apixaban patients were more likely to have greater proportions of
baseline comorbidities and higher CHA2DS2-VASc and HAS-BLED scores. After adjusting
for baseline clinical and demographic characteristics, patients prescribed rivaroxaban were
more likely to experience any bleeding (HR: 1.35, 95% confidence interval [CI]: 1.26–1.45),
CRNM bleeding (HR: 1.38, 95% CI: 1.27–1.49), and major inpatient bleeding (HR: 1.43,
95% CI: 1.17–1.74), compared to patients prescribed apixaban. Dabigatran patients had
similar bleeding risks as apixaban patients. In conclusion, NVAF patients treated with rivar-
oxaban appeared to have an increased risk of any bleeding, CRNM bleeding, and major
inpatient bleeding, compared to apixaban patients. There was no significant difference in
any bleeding, CRNM bleeding, or inpatient major bleeding risks between patients treated
with dabigatran and apixaban.
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Introduction
Atrial fibrillation (AF) increases the risk of stroke and systemic embolism, and AF-related
strokes have higher mortality, disability, costs, and risk of recurrent stroke compared to non-
AF related strokes [1,2]. Oral anticoagulation with warfarin reduces the risk of stroke by 64%,
and all-cause mortality by 26%, compared to control or placebo [3]. However, interactions
with food and other drugs, variability in metabolism, a delayed onset of action, and the neces-
sity of regular anticoagulation monitoring are limitations of warfarin therapy as well as a sig-
nificant risk of major bleeding, particularly if anticoagulation control is poorly managed [4–6].
One population-based cohort study reported a major bleeding rate of 3.8% per person-year
over a 5-year follow-up period [7]. This increased risk of bleeding with warfarin may lead to
more discontinuations of oral anticoagulants, thus exposing patients to a risk of stroke and
mortality.
Currently, non-vitamin K antagonist oral anticoagulants (NOACs) offer relative efficacy,
safety, and convenience compared to warfarin. These drugs can be given in fixed doses without
routine coagulation monitoring, and they have minimal drug and food interactions [7,8]. In
clinical trials, NOACs were non-inferior or superior to warfarin for the prevention of stroke or
systemic embolism in moderate-to-high risk patients with non-valvular AF, and were also
non-inferior or superior to warfarin in terms of safety, with regard to major and intracranial
bleeding [9]. However, clinical trials are limited by strict inclusion/exclusion criteria, and the
generalizability to everyday clinical practice requires post-licensing ‘real world’ observational
studies.
With the recent licensing and availability of NOACs, including dabigatran etexilate mesy-
late, rivaroxaban, apixaban, and edoxaban, data are needed on their comparative safety profile
in many countries. Dabigatran was approved in the United States in 2010, while rivaroxaban,
apixaban, and edoxaban were approved in 2011, 2012, and 2015, respectively.
The objective of this retrospective claims observational cohort study was to compare the
risk of bleeding among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban,
dabigatran, or rivaroxaban.
Materials and methods
This is a retrospective observational cohort study using insurance claims data from the Truven
MarketScan Commercial Claims and Encounter and Medicare Supplemental & Coordination
of Benefits Early View Database incurred from 01JAN2013-31OCT2014 to capture the real-
world experience of NVAF patients who were either new initiators or switchers from warfarin.
The database captures person-specific clinical utilization among approximately 100 payers of
large employers, health plans, and government and public organizations in the United States,
with more than 196 million unique patients since 1995. The database included annual insur-
ance claims of inpatient, outpatient, emergency room, pharmacy, behavioural health care, and
enrollment data for more than 94 million insured individuals, their dependents for active
employees, early retirees, Consolidated Omnibus Budget Reconciliation Act (COBRA) health
plan continuers, and Medicare-eligible retirees with employer-sponsored private health insur-
ance and employer-provided Medicare Supplemental plans in the United States [10]. Data
extraction for the purpose of this study was compliant with the Health Insurance Portability
and Accountability Act (HIPPA).
The study population consisted of patients with an AF diagnosis claim (N = 1,209,729) dur-
ing the study period. Patients were identified based on at least 1 inpatient or 2 outpatient
claims that were at least 30 days apart, with a primary or secondary diagnosis of AF (Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]: 427.3).
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The first AF diagnosis claim during the study period was defined as the date of AF diagnosis
for this population. As documented in claims data, we excluded transient perioperative AF
patients and patients with valvular heart disease or hyperthyroidism at the time of AF diagno-
sis and women who were pregnant during the study period. Transient perioperative AF
patients were identified as patients who had cardiac surgery procedures (ICD-9-CM: 35–39)
up to 30 days before the AF diagnosis date. Valvular heart disease was identified based on inpa-
tient or outpatient diagnosis of mitral stenosis or prosthetic heart valve (ICD-9-CM: 394, 396,
424, or 746). Hyperthyroidism was defined as having an inpatient or outpatient diagnosis of
hyperthyroidism or thyrotoxicosis (ICD-9-CM: 242).
NVAF patients who had unique pharmacy claims for apixaban, dabigatran, or rivaroxaban
on or after their AF diagnosis date were identified (n = 146,141) from 01JAN2013-
31OCT2014. The date of the first prescription claim was identified as the index date. The pop-
ulation included new initiators of unique NOACs and those who switched from warfarin.
Allowing warfarin experienced patients in the study population makes it more representative
of ‘real-world’ practice. All patients had 12 months of continuous enrollment prior to their
index date. Patients with bleeding, stroke, or transient ischemic attack (TIA) within 30 days
prior to or on the index date were excluded to avoid ambiguity about timing of treatment initi-
ation and occurrence of events. Patients who had a different NOAC prescription 6 months
before the index date were excluded (Fig 1).
Follow-up started after the index date and ended with the occurrence of bleeding, health
plan disenrollment, discontinuation, switch of therapy, or 6 months after treatment initiation,
whichever came first. Discontinuation of therapy was defined as no evidence of index prescrip-
tions for 30 days from the last day of supply of the last filled prescription. The date of discon-
tinuation was the last day of supply of the last filled prescription. During follow-up, if the
NOAC initiator had a pharmacy claim for another NOAC, the patient was censored on the
first date of the new drug’s pharmacy claim.
Any bleeding, including major and clinically relevant non-major (CRNM) bleeding, was
defined using inpatient or outpatient claims with a primary diagnosis of bleeding. Inpatient
major bleeding was identified based on inpatient claims, with major bleeding as the primary
diagnosis for a hospitalization (any visit to a hospital for haemorrhage). The definition of
major bleeding was modified from a published administrative claims-based algorithm and
captures major bleeding at key sites including but not limited to intracranial, gastrointestinal
(GI), liver, splenic, and ocular hemorrhage requiring hospitalization with a diagnosis for
bleeding [11]. Inpatient major bleeding was further categorized into intracranial haemorrhage
(ICH), GI, and other bleeding. The ICD-9-CM codes used to identify bleeding are listed in the
Supplementary Material.
Baseline patient characteristics during the 12-month period before or on the index date
were determined. Demographic factors included age on the index date, sex, health plan type,
and geographic region. Baseline comorbidities were identified based on inpatient or outpatient
claims with diagnoses of interest. Clinical prediction risk scores, including Charlson Comor-
bidity Index (CCI), CHADS2 and CHA2DS2-VASc stroke risk, and HAS-BLED bleed risk
scores were calculated as allowed by the availability of the data [12–15]. The CHADS2 risk
index was based on a point system in which 2 points are assigned for a history of stroke or a
transit ischemic attack and 1 point each is assigned to age�75 years, a history of hypertension,
a history of diabetes mellitus, or a heart failure. CHADS2-VASc score was calculated with fur-
ther consideration for vascular disease. The system will include 1 point for congestive heart
failure, hypertension, diabetes mellitus, vascular disease (prior myocardial infarction [MI],
peripheral artery disease, or aortic plaque), aged 65–74, and female, and 2 points for age�75,
stroke/TIA/thromboembolic disease. Modified HAS-BLED score was calculated to
Bleeding risks and anticoagulants in atrial fibrillation
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approximate bleed risk. One point was assigned to patients with 1) hypertension (ideally sys-
tolic blood pressure >160 mm hg, but for this study, ICD-9 code was used), 2) abnormal renal
function, 3) abnormal liver function, 4) stroke, 5) history of bleeding or predisposition (ane-
mia), 6) elderly (aged >65 years), 7) concomitant antiplatelet or nonsteroidal anti-inflamma-
tory drugs, and 8) alcohol abuse [15].
Prior stroke and bleeding in the baseline period were also reported. Concomitant use of
antiplatelets, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting-
enzyme (ACE) inhibitors, statins, and other anticoagulants 120 days preceding or on the index
date were identified based on pharmacy claims. Patients who switched from warfarin to an
NOAC were identified. Index NOAC dosage was categorized as reduced (apixaban 2.5 mg
twice a day; dabigatran 75 mg twice a day; rivaroxaban 15 mg once a day), standard (apixaban
5 mg twice a day; dabigatran 150 mg twice a day; rivaroxaban 20 mg once a day), or unknown.
Fig 1. Patient selection criteria. AF: atrial fibrillation; NOAC: non-vitamin K antagonist oral anticoagulant; NVAF: non-valvular atrial fibrillation; OAC: oral
anticoagulant.
https://doi.org/10.1371/journal.pone.0205989.g001
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Statistical analysis
Descriptive statistics of patient characteristics were summarized as mean (Standard Deviation,
SD), Median (interquartile range, IQR). Pairwise comparisons were conducted between dabi-
gatran and apixaban as well as between rivaroxaban and apixaban using Pearson’s chi-square
test and the Kruskal-Wallis test for categorical and continuous variables, respectively. Overall
annualized rates of inpatient bleeding were calculated for the first 6 months. Time-to-bleeding
was modelled using Cox proportional hazard regression. Multivariate modeling was per-
formed with the adjustment of baseline risk factors including age, gender, baseline comorbidi-
ties, and medications. Risk of bleeding, when comparing dabigatran or rivaroxaban versus
apixaban, was expressed as adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).
Statistical significance was determined using 2-sided tests with alpha = 0.05 and reported as p-
values<0.001 (���), <0.01 (��), <0.05 (�)
Two sensitivity analyses were conducted. First, a sensitivity analysis was conducted using
only patients who received the standard dosage (apixaban 5 mg twice a day; dabigatran 150 mg
twice a day; rivaroxaban 20 mg once a day). Second, a sensitivity analysis based on inverse
probability treatment weighting (IPTW) was performed. A multinomial logistic model with
treatment group as response and covariates included in the Cox regression adjusted models
was fit to calculate the weights. Weighted Cox proportional hazards models were used to esti-
mate the time-to-inpatient major bleeding in the dabigatran and rivaroxaban cohorts com-
pared with the apixaban cohort. All analyses were conducted using SAS Windows 9.3 (SAS
Institute Inc., Cary, NC).
Results
The eligible study population included 8,785 apixaban, 20,963 dabigatran, and 30,529 rivaroxa-
ban patients. Of the 32,800 patients, the median follow-up duration was 184 days (interquartile
range [IQR] 89–312) for apixaban, 553 days (IQR 341–619) for dabigatran, and 300 days (IQR
151–505) for rivaroxaban patients. The average age was 70 years for both apixaban and dabiga-
tran patients and 68 years for rivaroxaban patients (Table 1). Clinical comorbidity profiles
were more similar between apixaban and rivaroxaban patients than between apixaban and
dabigatran patients. Apixaban patients had greater proportions of clinical comorbidities com-
pared to both dabigatran and rivaroxaban patients, with higher overall CCI scores, higher
stroke and bleeding risk scores, and greater use of antiplatelet drugs prior to the index medica-
tion; apixaban patients were more likely to have switched from warfarin (Table 1).
The unadjusted bleeding rates are shown in Table 2, and the cumulative incidence of major
bleeding is represented in Fig 2. After the adjustment of baseline patient characteristics–medi-
cation use, dosage, and switching from warfarin–patients treated with rivaroxaban were signif-
icantly more likely to have any bleeding (HR: 1.35, 95% CI: 1.26–1.45) or CRNM bleeding
(HR: 1.38, 95% CI: 1.27–1.49) within 6 months of treatment initiation compared to those
treated with apixaban (Table 3).
After adjusting for baseline characteristics, there was a 43% (95% CI: 1.17–1.74) increased
adjusted risk of inpatient major bleeding for rivaroxaban patients as compared to apixaban
patients (Table 4). This effect was mainly observed in the risk of GI and other inpatient major
bleeding with rivaroxaban as compared to apixaban, with a 51% (95% CI: 1.18–1.92) increased
adjusted risk of GI inpatient bleeding, and a 58% (95% CI: 1.13–2.22) increased adjusted risk
of other inpatient major bleeding.
No significant differences were found between dabigatran and apixaban patients for any
bleeding, CRNM bleeding, or inpatient major bleeding. The sensitivity analysis to assess the
standard dose treatment effect on risk of major bleeding showed similar trends of significantly
Bleeding risks and anticoagulants in atrial fibrillation
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Table 1. Baseline characteristics of non-valvular atrial fibrillation (NVAF) patients who initiated apixaban, dabigatran, or rivaroxaban.
Patient Characteristics Apixaban
(n = 8,785) (Reference)
Dabigatran (n = 20,963) Rivaroxaban (n = 30,529)
Age, Mean (SD), Median (IQR) 70 (12)
70 (61,80)
70 (11)
70 (61,79)
68 (12)���
68 (60,78)
Aged�75, % 38.1 38.0 34.5���
Female, % 37.3 34.7��� 36.8
Myocardial Infarction, % 7.1 5.0��� 6.9
Peripheral vascular disease, % 8.8 7.4��� 8.4
Congestive Heart Failure, % 19.0 17.3��� 18.6
Diabetes mellitus, % 30.0 30.9 29.2
Renal Disease, % 10.8 8.5��� 8.9���
Malignancy, % 12.1 11.3� 12.6
Hypertension, % 73.6 66.2��� 69.2���
Anemia, % 3.6 2.6��� 3.5
Alcohol Abuse, % 0.6 0.4�� 0.7
Pulmonary Embolism, % 1.1 0.6��� 4.5���
Deep Vein Thrombosis, % 0.9 0.6� 3.1���
Cardioversion, % 9.3 8.9 9.0
History of Bleeding 16.8 15.6�� 18.3��
History of Stroke/ transient ischemic attack 5.8 3.8��� 5.2�
CHADS2, Mean (SD) 1.7 (1.1) 1.6 (1.1)
��� 1.6 (1.1)���
0 12.8 14.5 15.6
1 32.5 34.3 34.0
2 32.8 33.3 30.8
3+ 21.9 17.8 19.7
CHA2DS2-VASc, Mean (SD) 2.5 (1.5) 2.4 (1.4)
��� 2.4 (1.5)���
0 8.3 9.0 10.8
1 19.3 19.2 20.9
2 24.0 27.5 24.2
3+ 48.5 44.3 44.1
HAS-BLED, Mean (SD) 1.9 (1.2) 1.8 (1.2)��� 1.8 (1.2)���
0 9.6 10.9 7.5
1 30.0 32.7 28.1
2 35.3 35.3 36.3
3+ 25.1 21.1 28.1
CCI score, Mean (SD) 1.8 (2.0) 1.6 (1.9)��� 1.8 (2.2)
0 32.7 34.7 33.8
1 23.6 25.8 24.4
2 16.4 15.2 15.0
3+ 27.3 24.4 26.9
Medication use 120 days preceding index dates, %
Use of antiplatelets 9.3 4.2��� 7.4���
Use of NSAIDs 7.1 12.3��� 7.5
ACE inhibitors 32.7 33.4 31.3�
Antidepressants/antipsychotics 18.2 18.6 19.4�
Angiotensin receptor blockers 22.2 21.7 21.3
Statins 52.2 54.2�� 48.3���
Other anticoagulants 1.5 0.9��� 2.8���
Switched from warfarin, % 17.3 4.4��� 15.7���
(Continued)
Bleeding risks and anticoagulants in atrial fibrillation
PLOS ONE | https://doi.org/10.1371/journal.pone.0205989 November 1, 2018 6 / 12
higher major risk with rivaroxaban compared to apixaban (Table 5). Additionally, the IPTW
sensitivity analysis demonstrated consistent trends with the main analysis (Table 6).
Discussion
In this study, our principal finding was that NVAF patients treated with rivaroxaban appeared
to have an increased risk of any bleeding, CRNM bleeding, and inpatient major bleeding com-
pared to patients treated with apixaban. There was no significant difference in any bleeding,
CRNM bleeding, or inpatient major bleeding between dabigatran and apixaban patients.
This large observational cohort study compares inpatient bleeding risks among NVAF
patients treated with the three NOACs: rivaroxaban, dabigatran, and apixaban. Despite greater
comorbidities and worse bleeding and stroke profiles among apixaban patients, these patients
experienced significantly less major inpatient bleeding, CRNM bleeding, or any bleeding
events compared to rivaroxaban patients, and had comparable bleeding event rates to dabiga-
tran patients. When compared with apixaban, rivaroxaban patients also showed significantly
Table 1. (Continued)
Patient Characteristics Apixaban
(n = 8,785) (Reference)
Dabigatran (n = 20,963) Rivaroxaban (n = 30,529)
Dosage ��� ���
Reduced 16.9 12.0 20.3
Standard 79.1 83.1 76.3
Unknown 4.0 4.9 3.4
���: p<0.001
��, p<0.01
�, p<0.05
ACE: angiotensin-converting-enzyme; CCI: Charlson Comorbidity Index; CHADS2: Congestive heart failure, Hypertension, Age�75 years, Diabetes mellitus, prior
Stroke, transient ischemic attack or thromboembolism; CHA2DS2-VASc: Congestive heart failure, Hypertension, Age�75 years, Diabetes mellitus, prior Stroke or
transient ischemic attack, Vascular disease, Age 65–74 years, Sex category; CHF: congestive heart failure; HAS-BLED: hypertension, Abnormal renal function,
Abnormal liver function, previous Stroke, prior major Bleeding or predisposition, Labile international normalized ratio; Elderly age (>65 years), Drugs predisposing to
bleeding, alcohol use; IQR: interquartile range; MI: myocardial infarction; NSAIDs: nonsteroidal anti-inflammatory drugs; NVAF: non-valvular atrial fibrillation; PVD:
peripheral vascular disease; SD: standard deviation; TIA: transient ischemic attack
https://doi.org/10.1371/journal.pone.0205989.t001
Table 2. Unadjusted annual cumulative incidence of bleeding among non-valvular atrial fibrillation (nvaf) patients who initiated apixaban, dabigatran, or
rivaroxaban.
Apixaban
(N = 8,785)
Dabigatran
(N = 20,963)
Rivaroxaban
(N = 30,529)
Bleeding N % Incidence
%/year
N % Incidence
%/year
N % Incidence
%/year
Any bleeding 962 11.0 39.5 2,828 13.5 37.7 4,855 16.0 53.5
Clinically relevant non-major bleeding 742 8.5 30.4 2,173 10.4 28.9 3,759 12.4 41.3
Inpatient Major Bleeding
Total 119 1.4 4.6 306 1.5 4.9 656 2.1 6.7
Intracranial haemorrhage 13 0.1 0.5 36 0.2 0.5 64 0.2 0.7
Gastrointestinal 77 0.9 3.0 211 1.0 2.7 447 1.5 4.6
Other 40 0.5 1.5 94 0.4 1.2 251 0.8 2.6
CRNM: clinically relevant non-major (bleeding); GI: gastrointestinal; ICH: intracerebral haemorrhage; NVAF: non-valvular atrial fibrillation
https://doi.org/10.1371/journal.pone.0205989.t002
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higher GI and other bleeding risks, and trended towards a higher ICH bleeding risk. Dabiga-
tran had similar risks with apixaban across various bleeding sites.
Previous studies used data from large clinical trials to compare the safety between NOACs,
which have been used to inform indirect comparisons and network meta-analyses [16]. Our
study is broadly supportive of clinical trial observations, and in the ROCKET-AF trial, rivarox-
aban had a comparable risk of bleeding to warfarin, whilst apixaban had significantly lower
Fig 2. Kaplan-meier curves of any major inpatient bleeding by treatment. Rivaroxaban has the highest cumulative probability of any inpatient
major bleeding. The overall Log-rank is p<0.0001.
https://doi.org/10.1371/journal.pone.0205989.g002
Table 3. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for any, major, and clinically relevant Non-Major (CRNM) bleeding during the first 6
months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban.
Bleeding Adjusted HR (Dabigatran
vs Apixaban)
P-value Adjusted HR (Rivaroxaban vs Apixaban) P-value
Any Bleeding 1.00 (0.93, 1.08) 0.88 1.35 (1.32, 1.45) <0.0001
CRNM Bleeding 1.01 (0.93, 1.10) 0.83 1.38 (1.27, 1.49) <0.0001
CI: confidence interval; CRNM: clinically relevant non-major (bleeding); HR: hazard ratio
https://doi.org/10.1371/journal.pone.0205989.t003
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bleeding risk compared to warfarin [17–19]. We also found less bleeding with dabigatran com-
pared to rivaroxaban, consistent with indirect comparison studies [20].
Few direct comparisons have been completed for apixaban, dabigatran, and rivaroxaban
patients in a real-world setting. Another observational study using MarketScan data and pro-
pensity score matching showed that dabigatran had similar risk of major bleeding compared
to apixaban and rivaroxaban, and apixaban had significantly lower risk of major bleeding com-
pared to rivaroxaban [21]. Our study showed consistent results with additional comparisons of
types of major bleeding and CRNM. Furthermore, in a more recent claims study using Optum
claims data, apixaban patients had a 50% and 61% lower risk of major bleeding compared to
dabigatran and rivaroxaban patients, respectively. There was no difference in the risk of ICH
between apixaban and dabigatran or rivaroxaban patients [22]. In another study using the
same data, apixaban patients also had a significantly lower risk of GI bleeding compared to
dabigatran and rivaroxaban patients [23].
In addition, previous real-world studies have compared the risk of major bleeding for
NOACs versus warfarin, the standard of care. Several real-world analysis comparing dabiga-
tran to warfarin on adjusted overall bleeding risks showed greater or non-significant differ-
ences in overall bleeding, but higher GI bleeding and lower ICH risks [24–27]. Nonetheless, a
recent study reported significantly lower overall major bleeding and ICH risks among dabiga-
tran patients compared to warfarin patients [28]. Abraham et al. found similar GI bleeding
risks when comparing dabigatran and rivaroxaban separately to warfarin using the Optum
dataset [29]. Furthermore, real-world studies focused on rivaroxaban versus warfarin have
shown no statistically significant difference in bleeding risk [21,28,30]. In addition, apixaban
patients have been shown to have consistently lower risk of major bleeding compared to warfa-
rin [21,28,31].
Based on large national claims data, our study adds novel evidence regarding the compara-
tive bleeding risks of apixaban, dabigatran, and rivaroxaban in patients with NVAF. This
Table 4. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during the first 6 months after treatment initiation compar-
ing Dabigatran and Rivaroxaban vs Apixaban among non-valvular atrial fibrillation (NVAF) patients.
Inpatient Major Bleeding Adjusted HR (Dabigatran
vs Apixaban)
P-value Adjusted HR (Rivaroxaban vs Apixaban) P-value
Any 0.89 (0.72, 1.10) 0.29 1.43 (1.17, 1.74) <0.01
Intracranial haemorrhage 0.95 (0.50, 1.80) 0.86 1.29 (0.71, 2.35) 0.41
Gastrointestinal 0.94 (0.72, 1.23) 0.67 1.51 (1.18, 1.92) <0.01
Other 0.84 (0.58, 1.22) 0.35 1.58 (1.13, 2.22) <0.01
CI: confidence interval; GI: gastrointestinal; HR: hazard ratio; ICH: intracerebral hemorrhage; NVAF: non-valvular atrial fibrillation
https://doi.org/10.1371/journal.pone.0205989.t004
Table 5. Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major
bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among non-valvular atrial fibrillation (NVAF)
patients.
Major Inpatient Bleeding Adjusted HR (Dabigatran
vs Apixaban)
P-value Adjusted HR (Rivaroxaban vs Apixaban) P-value
Any 0.84 (0.67, 1.06) 0.14 1.38 (1.11, 1.70) <0.01
Intracranial haemorrhage 1.00 (0.47, 2.14) 0.99 1.49 (0.73, 3.05) 0.27
Gastrointestinal 0.82 (0.62, 1.10) 0.19 1.35 (1.04, 1.76) 0.03
Other 0.86 (0.57, 1.30) 0.48 1.52 (1.05, 2.21) 0.03
CI: confidence interval; GI: gastrointestinal; HR: hazard ratio; ICH: intracerebral hemorrhage; NVAF: non-valvular atrial fibrillation
https://doi.org/10.1371/journal.pone.0205989.t005
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population includes patients who were warfarin naïve and warfarin experienced, which makes
it more representative of true clinical practice. Many prior studies only include treatment-
naïve patients. Clearly, more real-world studies regarding bleeding risks and use of NOACs
are still warranted.
Limitations
First, health insurance databases include patients with varied risk profiles, and patients with a
higher risk of major bleeding were more likely to use apixaban. Second, patients on all dosages of
apixaban, dabigatran, and rivaroxaban were included in the study population. As expected, previ-
ous studies have shown that increased dosages are positively associated with bleeding events. Sen-
sitivity analysis using only standard dosage found comparable results. Third, compared with
clinical trials, no causal relation can be drawn in this retrospective cohort study. Additionally,
there are wide ranges of comorbidities among the cohorts, and although baseline characteristics
were adjusted, some residual confounding is likely because of unmeasured confounders [32]. The
mean length of follow-up for patients treated with apixaban was significantly shorter compared to
those treated with dabigatran and rivaroxaban. Survival methodology was used to account for the
varied follow-up length; however, apixaban-related bleeding events could have occurred later
than the other NOACs, which could have affected the results. Given the distinct separation in the
cumulative incidence, we would expect minimal impact on the results.
Furthermore, there are inherent limitations of claim data, such as coding errors and miss-
ing data. Comorbidities were presented in the dataset using ICD-9-CM diagnosis codes. Labo-
ratory data, including creatinine clearance, are not available in the claims database, so
diagnosis codes were used to determine comorbidities. Additionally, with a claims database,
medication as filled may not reflect true medication use [33]. Nonetheless, this study used a
large database of nationally representative commercially insured patients and is one of the first
studies to compare the safety between NOACs.
Conclusions
In conclusion, NVAF patients treated with rivaroxaban appeared to have an increased risk of
any bleeding, CRNM bleeding, and major inpatient bleeding compared to patients treated
with apixaban. There was no significant difference in any bleeding, CRNM bleeding, or inpa-
tient major bleeding between dabigatran and apixaban patients. These data may help guide
decision-making in clinical practice.
Acknowledgments
Allison Keshishian and Qisu Zhang of STATinMED Research provided editorial assistance in
the preparation of this manuscript.
Table 6. Sensitivity analysis—Inverse probability treatment weighting IPTW analyses: Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpa-
tient major bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among nvaf patients.
Inpatient Major Bleeding Adjusted HR (Dabigatran
vs Apixaban)
P-value Adjusted HR (Rivaroxaban vs Apixaban) P-value
Any 1.02 (0.81, 1.28) 0.88 1.54 (1.26, 1.89) <0.01
Intracranial haemorrhage 1.06 (0.55, 2.04) 0.87 1.45 (0.79, 2.66) 0.23
Gastrointestinal 1.10 (0.82, 1.47) 0.52 1.65 (1.28, 2.11) <0.01
Other 0.98 (0.66, 1.46) 0.92 1.69 (1.20, 2.38) <0.01
CI: confidence interval; GI: gastrointestinal; HR: hazard ratio; ICH: intracerebral hemorrhage; NVAF: non-valvular atrial fibrillation
https://doi.org/10.1371/journal.pone.0205989.t006
Bleeding risks and anticoagulants in atrial fibrillation
PLOS ONE | https://doi.org/10.1371/journal.pone.0205989 November 1, 2018 10 / 12
Author Contributions
Conceptualization: Ping G. Tepper, Jack Mardekian, Cristina Masseria, Hemant Phatak, Shi-
tal Kamble, Younos Abdulsattar, William Petkun, Gregory Y. H. Lip.
Formal analysis: Ping G. Tepper.
Writing – original draft: Ping G. Tepper, Gregory Y. H. Lip.
Writing – review & editing: Ping G. Tepper, Jack Mardekian, Cristina Masseria, Hemant Pha-
tak, Shital Kamble, Younos Abdulsattar, William Petkun, Gregory Y. H. Lip.
References
1. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to
incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36(6):
1115–1119. https://doi.org/10.1161/01.STR.0000166053.83476.4a PMID: 15879330
2. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, et al. Prevention of atrial fibrillation:
report from a national heart, lung, and blood institute workshop. Circulation. 2009; 119(4): 606–618.
https://doi.org/10.1161/CIRCULATIONAHA.108.825380 PMID: 19188521
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who
have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857–867. PMID: 17577005
4. Gallego P, Roldan V, Marı´n F, Romera M, Valde´s M, Vicente V et al. Cessation of oral anticoagulation
in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Hae-
most. 2013; 110(6): 1189–1198. https://doi.org/10.1160/TH13-07-0556 PMID: 24096615
5. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists
in heart disease: current status and perspectives (Section III): position paper of the ESC Working Group
on Thrombosis—task force on anticoagulants in heart disease. Thromb Haemost. 2013; 110(6): 1087–
1107. https://doi.org/10.1160/TH13-06-0443 PMID: 24226379
6. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and
prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual
Outcomes. 2008; 1(2): 84–91. https://doi.org/10.1161/CIRCOUTCOMES.108.796185 PMID:
20031794
7. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage
during warfarin therapy for atrial fibrillation. CMAJ. 2013; 185(2): E121–E127. https://doi.org/10.1503/
cmaj.121218 PMID: 23184840
8. Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anti-
coagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost. 2014; 111(5): 783–
788. https://doi.org/10.1160/TH13-12-1032 PMID: 24573511
9. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison
of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a
meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962. https://doi.org/10.1016/S0140-
6736(13)62343-0 PMID: 24315724
10. Danielson E. Health Research Data for the Real World: The MarketScan® Databases. Ann Arbor, MI,
Truven Health Analytics; 2014.
11. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database
case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf.
2011; 20(6): 560–566. https://doi.org/10.1002/pds.2109 PMID: 21387461
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity
in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–383. PMID:
3558716
13. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010; 123(6):
484–488. https://doi.org/10.1016/j.amjmed.2009.12.013 PMID: 20569748
14. Rolda´n V, Marı´n F, Ferna´ndez H, Manzano-Fernandez S, Gallego P, Valde´s M, et al. Predictive value
of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population
with atrial fibrillation receiving anticoagulant therapy. Chest. 2013; 143(1): 179–184. https://doi.org/10.
1378/chest.12-0608 PMID: 22722228
15. Pisters R, Lane Da, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-
BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Chest. 2010; 138(5): 1093–1100. https://doi.org/10.1378/chest.10-0134 PMID: 20299623
Bleeding risks and anticoagulants in atrial fibrillation
PLOS ONE | https://doi.org/10.1371/journal.pone.0205989 November 1, 2018 11 / 12
16. Skjøth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabi-
gatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. an indirect comparison analy-
sis. Thromb Haemost. 2014; 111(5): 981–988. https://doi.org/10.1160/TH14-02-0118 PMID: 24577485
17. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891. https://doi.org/10.1056/
NEJMoa1009638 PMID: 21830957
18. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of
rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Riv-
aroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014; 130(2): 138–
146. https://doi.org/10.1161/CIRCULATIONAHA.113.005008 PMID: 24895454
19. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus war-
farin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992. https://doi.org/10.1056/
NEJMoa1107039 PMID: 21870978
20. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for
efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012; 60(8):
738–746. https://doi.org/10.1016/j.jacc.2012.03.019 PMID: 22575324
21. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of
major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivar-
oxaban, or warfarin. Thromb Haemost. 2016; 116(5): 975–986. https://doi.org/10.1160/TH16-05-0403
PMID: 27538358
22. Noseworthy PA, Yao X, Abraham NS Sangaralingham LR, McBane RD, Shah ND. Direct comparisons
of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation.
Chest. 2016; 150(6): 1302–1312. https://doi.org/10.1016/j.chest.2016.07.013 PMID: 27938741
23. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct
oral anticoagulants: a large population-based study. Gastroenterology. 2017; 152(5): 1014–1022.
https://doi.org/10.1053/j.gastro.2016.12.018 PMID: 28043907
24. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular,
bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalv-
ular atrial fibrillation. Circulation. 2015; 131(2): 157–164. https://doi.org/10.1161/CIRCULATIONAHA.
114.012061 PMID: 25359164
25. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA
Intern Med. 2015; 175(1): 18–24. https://doi.org/10.1001/jamainternmed.2014.5398 PMID: 25365537
26. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of
dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015; 114(6):
1277–1289. https://doi.org/10.1160/TH15-06-0497 PMID: 26446507
27. Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, et al. A comparison of the safety and
effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare
system. Thromb Haemost. 2015; 114(6): 1290–1298. https://doi.org/10.1160/TH15-06-0453 PMID:
26446456
28. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and
safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am
Heart Assoc. 2016; 5(6): e003725. https://doi.org/10.1161/JAHA.116.003725 PMID: 27412905
29. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastroin-
testinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;
350: h1857. https://doi.org/10.1136/bmj.h1857 PMID: 25910928
30. Laliberte´ F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, et al. Real-world comparative
effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med
Res Opin. 2014; 30(7): 1317–1325. https://doi.org/10.1185/03007995.2014.907140 PMID: 24650301
31. Adeboyeje G, Sylwestrzak G, White J, Rosenberg A, Abarca J, Crawford G, et al. Comparative effec-
tiveness and safety of anticoagulant therapy with warfarin, dabigatran, apixaban, or rivaroxaban in
patients with nonvalvular atrial fibrillation. Circ Card Qual Outcomes. 2016; 9(Suppl 2):A2.
32. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagu-
lant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015; 115(8): 1095–
1101. https://doi.org/10.1016/j.amjcard.2015.01.539 PMID: 25724781
33. Lauffenburger JC, Balasubramanian A, Farley JF, Critchlow CW, O’Malley CD, Roth MT, et al. Com-
pleteness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug
Saf. 2013; 22(8): 899–906. https://doi.org/10.1002/pds.3458 PMID: 23696101
Bleeding risks and anticoagulants in atrial fibrillation
PLOS ONE | https://doi.org/10.1371/journal.pone.0205989 November 1, 2018 12 / 12
